Description
Size: 536 amino acids; 59.835 KDa. Src is 59.6 KDa in size and has a domain structure comprised of six distinct functional regions (see figure above). These include an N-terminal SH4 domain that contains a lipid-modification sequence allowing targeting of Src to cellular membranes, and an adjacent, poorly-conserved region thus being unique to each Src family member. SH3 and SH2 domains adjacent to the N-terminus facilitate protein-protein interactions between Src and its interacting proteins whilst the SH1 domain allows ATP and substrate binding and has tyrosine kinase activity; autophosphorylation of Y419 within this domain is required for the maximum kinase activity of Src. The negative regulatory tail of Src contains a tyrosine at 530, the phosphorylation of which promotes a conformational change to produce an inactive Src molecule. Sequences within the Cterminus of Src have been recently identified to facilitate protein-protein interactions have been shown to regulate Src function in addition to its kinase activity.
Expression
Ubiquitously expressed but with particularly high levels in brain tissue, osteoclasts and platelets.
Localisation
Predominantly cytoplasmic and/or plasma mem-brane, the latter due to myristolation of the N-terminus. Activated Src has also been reported in the cell nucleus in some tumour tissues.
Function
Src can interact with a diverse array of cellular factors allowing it to regulate a variety of normal and oncogenic processes that ultimately result in cell proliferation, differentiation, survival, adhe-sion, motility, invasion and angiogenesis (Thomas and Brugge, 1997; Summy and Gallick, 2003) . Such interacting partners include receptor tyrosine kinases (e.g. the EGF receptor family (Biscardi et al., 1998) ), integrins (Galliher and Schiemann, 2006; Huveneers et al., 2007) , cell-cell adhesion molecules (Giehl and Menke, 2008) , in addition to STATs (Silva, 2004) , FAK (Brunton and Frame, 2008) , the adaptor protein p130Cas (Chang et al., 2008) and GPCRs (McGarrigle and Huang, 2007) . Importantly, Src can also interact with the oestrogen receptor (Weatherman, 2008) , where it has been shown to be pivotal in both non-genomic ER activation of signalling pathways and gene transcription events. The ability of Src to function as both an effector and regulator of receptor-induced signalling allows it to mediate cross-talk between normally distinct signalling pathways and thus regulate a wide variety of both normal and oncogenic processes, including proliferation, differentiation, survival, adhesion, motility, invasion and angiogenesis. Homology c-Src is the prototypic member of a family of nine nonreceptor tyrosine kinases which share the same domain structure (Src, Fyn, Yes, Lyn, Lck, Hck, Blk, Fgr and Frk) (Erpel and Courtneidge, 1995) and are expressed in vertebrates. All Src family members have the same basic structure of an N-terminal, unique domain containing a myristylation site and frequently a palmitoylation site; regulatory SH3 and SH2 domains; a catalytic domain that has its active site wedged between the two lobes of the molecule, and a Cterminal regulatory tail that contains the hallmark regulatory tyrosine residue (Tyr527 in Src). The activity of Src family kinases is suppressed upon phosphorylation of Tyr527, allowing binding of the Cterminal domain to the SH2 domain. The SH2 and SH3 domains bind phosphotyrosine and proline-rich peptides, respectively; through these interactions, they participate in intra-and intermolecular regulation of kinase activity, as well as localization and substrate recognition. 
Mutations

Somatic
The SRC family of kinases is rarely mutated in primary human tumours, although apparently scarce, a truncating and activating mutation in Src (at aa 531) has been described for a small subset of advanced-stage colorectal cancers (Irby et al., 1999) . 
Implicated in
Colorectal cancer
Disease
Increased Src activity has been widely described in colorectal tumour tissue compared with normal epithelia and within colon polyps, particularly those displaying a malignant phenotype (DeSeau et al., 1987; Cartwright et al., 1994) . In colorectal cancer tissue studies, elevated Src kinase activity is associated with a poor clinical outcome (Aligayer et al., 2002) . In vitro studies suggest that in colon cancer, Src may contribute more to disease spread than to increased proliferation (Jones et al., 2002) .
Breast cancer
Disease Src kinase activity is increased in breast cancer tissue compared to normal tissues (Verbeek et al., 1996) . In vivo animal models suggest that Src activity is elevated in breast tumours over-expressing HER2 and interaction between Src and erbB family members may promote the develop-ment of a more aggressive disease clinically (Biscardi et al., 2000; Tan et al., 2005) . Physical interactions between Src and growth factor receptors are reported in breast cancer tissues and cells, particularly with receptor tyrosine kinases of the EGFR family allowing Src to regulate signal-ling pathways that may contribute to aggressive breast cancer cell behaviour. Src is also intimately involved with Her2 pathway signalling in breast cancer, the result of which is the promotion of an invasive phenotype (Vadlamudi et al., 2003; Tan et al., 2005) . Oestrogenic signalling plays a critical role in promoting breast cancer cell growth where ligand-induced activation of oestrogen receptors (ERs) results in gene transcription mediated by the ER, in complex with various co-activators/co-repressor molecules. In such cases, Src is able to potentiate ER-mediated, AF-1 dependent gene transcription through indirect phosphorylation of nuclear ER via ERK1/ERK2 (Feng et al., 2001) and Akt (Campbell et al., 2001; Shah et al., 2005) and through regulation of FAK-p130CAS-JNK signalling pathway activity and the subsequent activation of co-activator molecules including CBP (PAG1) and GRIP1 (NCOA2). Furthermore, Src appears to mediate non-genomic ER signalling through ERK and Akt pathways (Castoria et al., 2001; Wessler et al., 2006) to regulate cellular proliferation and survival (Castoria et al., 1999; Migliaccio et al., 2000) . That Src is involved in both EGFR/Her2 and ER signalling has led to Src being implicated in growth factor-ER cross talk mechanisms in breast cancer and the development of endocrine resistance (Arpino et al., 2008; Massarweh and Schiff, 2006; Hiscox et al., 2006; Hiscox et al., 2009 ).
Hematopoietic cancers
Disease
The majority of Src family kinases are highly expressed in cells of a hematopoietic origin where they are suggested to regulate growth and prolifera-tion. Src itself is, along with related family kinase members, are implicated in imatinib-resistant, BCR-ABL-expressing CML (Li, 2008) .
Other tumour types
Disease Src protein and activity have been identified as being increased in a number of other tumour types including gastric, pancreatic, lung and ovarian tumours compared to normal tissue suggesting a possible role for Src in these tumours.
